` Zurich 2013 | Sachs Associates
  HOME  |  CONTACT  
  spi2012  
 
sachs associates   13th ANNUAL
BIOTECH IN EUROPE INVESTOR FORUM
    30th September – 1st October 2013 • Hilton Zurich Airport Hotel, Switzerland
 
  spi2012  
 
 
Register Now
 
Register
To Exhibit
 
Register
To Present
 
sachs sachs sachs sachs sachs sachs sachs
 
sachs sachs
 
 
2013 PRESENTING COMPANIES INCLUDE:
Activiomics Ltd
ActoGeniX NV
Adrenomed AG
Algiax Pharmaceuticals GmbH
Alpine Institute for Drug Discovery
ALRISE Biosystems
AM-Pharma
AnaptysBio, Inc.
Anergis SA
Antisense Pharma GmbH
apceth GmbH & Co. KG
Asceneuron SA
Athera Biotechnologies AG
Atlas Genetics
Biocartis NV
BioCrea GmbH
BiolineRx Ltd
BioScale
Biotechpharma
BioVariance
Bioxodes
CAP-CMV GmbH
Cardiox Corporation
Cell2B Advanced Therapeutics S.A.
Curetis
dacadoo ag
Delenex Therapeutics
Diagnoplex
Dicerna Pharmaceuticals
eADMET GmbH
EffRx Pharmaceuticals SA
Enterome
Epigenomics AG
ERYTECH Pharma
Esteve
Forendo Pharma
Galecto Biotech
Galmed Pharmaceuticals Ltd
GeneFirst Ltd
Gentium SpA
Glycostem Therapeutics
Heptares Therapeutics
Hermo Pharma
HFM- Hybrid Fusion Medicals
immatics biotechnologies
ImmunID
InFlectis BioScience
Invion Limited
Kala Pharmaceuticals
Medicenna Therapeutics, Inc.
MEDLUMICS
Metys Pharmaceuticals
Nanobiotix
Newron Pharmaceuticals SpA
NOXXON Pharma AG
NLT Spine Ltd
Numab AG
OCT Clinical Trials
Origimm
Oryzon
Oxford Biomedica
PAION AG
Panoptes Pharma
PCI Biotech ASA
Phenex
PIQUR Therapeutics AG
PolyTherics
Poxel Pharma
Priaxon AG
Probiodrug
Promethera Biosciences
Protectimmun GmbH
Provista Diagnostics Inc
Sensorion Pharma
Signature Diagnostics AG
SironRx
Soluventis GmbH
Som Biotech
Spiber Technologies AB
T-cell Europe GmbH
TNC Bio
TRION Pharma GmbH
ugichem GmbH
Virogates
Wilson Therapeutics
Zarzatech Europe Sarl

To see the 2012 Presenting Companies click here >

 

 

About 13th Annual Biotech in Europe Investor Forum

The 13th Annual Biotech in Europe Investor Forum will be held on 30th September – 1st October 2013 in the Hilton Zurich Airport Hotel, Switzerland. The forum is recognised as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners. We expect around 350 delegates and 80 presenting companies.

The two-day conference programme will give you access to some of the leading players in the industry and will provide you with truly excellent networking opportunities as it boasts an online partnering system with 500 meeting slots available for all attendees to book before the event.

Conference Timings:
Conference registration starts from 08.00 on 30th September and 1st October.
30th September - Program runs from 08.20 until 18.00 with reception running until 20.00.
1st October – Program runs from 08.30 until 16.00.
Meeting rooms are available during conference hours.


The program will comprise of plenary panels including:
  • Alain Huriez, Venture Partner, Advent Venture Partners and Chairman, EPEMED
  • Professor Dr Andre Rosenthal, CEO, Signature Diagnostics AG
  • Anja König, Managing Director, Novartis Venture Fund
  • Bart Wuurman, CEO, Lanthio Pharma BV
  • Bernd Goergen, Senior Investment Manager, High-Tech Gründerfonds Management
  • Dr Bernd Muehlenweg, CBO, Nanobiotix
  • Beth Jacobs, Managing Partner, Excellentia Global Partners
  • Carlos Buesa, CEO, Oryzon SA
  • Carole Nuechterlein, Head, F. Hoffmann-La Roche AG Roche Venture Fund
  • Chris Britten, Head Business Development, Sanofi Pasteur-MSD
  • Chris Maggos, Alpine Institute for Drug Discovery
  • Christina Takke, Partner, Forbion Capital Partners
  • Corinne Savill, Head Business Development and Licensing, Novartis Pharma AG
  • David Pinniger, Fund Manager, Polar Capital
  • David Urech, Co-CEO, CSO, Numab AG
  • Deborah Harland, VP & President, SR One
  • Dirk Beher, CSO, Asceneuron SA
  • Douglas M. Famborough, CEO, Dicerna Pharmaceuticals, Inc.
  • Dr Edward D. Blair, Managing Director, Integrated Medicines Ltd.
  • Elena Startseva, Head of Business Development, OCT Clinical Trials
  • Eric Halioua, Co-Founder and CEO, Promethera Biosciences
  • Eric Massou, CFO, Poxel Pharmaceuticals
  • Esteban Pombo-Villar, COO, Oxford BioTherapeutics
  • Dr Fintan Walton, Founder and CEO, PharmaVentures Ltd.
  • Dr Frank Grams, VP, Head of R&D Alliance Management & Transactions, Sanofi
  • Genghis Lloyd-Harris, Partner, Abingworth Management LLP
  • Graeme Martin, President and CEO, Takeda Research Investment, Inc.
  • Hamza Suria, President & CEO, AnaptysBio, Inc.
  • Hartmut Ruetten, Head Translational Medicine Diabetes R&TM, Sanofi
  • Heinz Schwer, Senior Director, MorphoSys AG
  • Dr Jaume Masana, Licensing & Strategic Partnering Director, Esteve
  • Jesús Martin-Garcia, General Partner, Eclosion2
  • John Clarkson, CEO, Atlas Genetics Ltd.
  • Jonathan Garen, Assistant Vice President Business Development, Forest Laboratories, Inc.
  • Judith Hills, Vice President, Corporate Business Development, Ipsen Biopharm Limited
  • Juhani Lahdenpera, CEO, Hermo Pharma Ltd.
  • Katya Smirnyagina, Partner, Capricorn Venture Partners
  • Keith Blundy, CEO, Cancer Research Technology
  • Lorenza Castellon, Independent Consultant
  • Magali Gibou, Senior Regulatory Affairs Manager, Transgene S.A.
  • Malcolm Weir, Co-Founder and Chief Executive Officer, Heptares Therapeutics Ltd.
  • Manfred Hosrt, Director Business Development, Merck & Co./MSD
  • Mark Bleckmann, Director & Head of Finance, immatics biotechnologies GmbH
  • Markus Hosang, General Partner, BioMedPartners AG
  • Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting
  • Nanna Lüneborg, Investment Director, Novo Seeds, Novo A/S
  • Oliver Schacht, CEO, Curetis
  • Peter E. Burckhardt, CEO, EVA – the Basel life sciences start-up agency
  • Peter Llewellyn-Davies,, CFO, Medigene AG
  • Dr Philippe Calais, CEO, Antisense Pharma GmbH
  • Pierre-Olivier Goineau, EVP & COO, ERYTECH Pharma SA
  • Rainer Metzger, VP, Global Head Business Development Pharma, QIAGEN
  • Rainer Strohmenger, General Partner, Wellington Partners
  • Rudi Pauwels, Executive Chairman & CEO, Biocartis
  • Sarah Holland, Global Head of Strategic Partnering, F. Hoffmann-La Roche Ltd.
  • Seong Chen, Project Leader, Strategic Initiatives, Global Business Development, F. Hoffmann-La Roche Ltd.
  • Stefan Weber, CEO, NEWRON PHARMACEUTICALS SPA
  • Dr Stefanos Theoharis, CBO, apceth GmbH & Co.
  • Stéphane Boissel, Executive Vice-President & Chief Financial Officer, Transgene
  • Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners
  • Thomas Jung, Chief Medical Officer, Delenex Therapeutics AG
  • Thomas Taapken, CEO/CFO, Epigenomics AG
  • Tim Knoterus, Business Development, AM-Pharma
  • Tom Kronbach, CEO, BioCrea
  • Vincent Charlon, CEO, Anergis
  • Vladimir Cmiljanovic, Chief Executive Officer, PIQUR Therapeutics AG
  • Wilder Fulford, Principal, Torreya Partners
  • Willem van Weperen, CEO, To-BBB Technologies BV
  • And More TBA...

NEW FOR 2013:
Personalised Medicine and Companion Diagnostics:
from development to market.

    A series of snapshot perspectives
    Chaired by:
  • Dr Edward D. Blair, Managing Director, Integrated Medicines Ltd.
  • Lorenza Castellon, Independent Consultant
  • Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting
    Speakers:
  • Rainer Metzger, VP Global Affairs Manager, QIAGEN
    Topic: cDx deals
  • Dr Hartmut Rütten, Head Translational Medicine Diabetes R&TM, Sanofi
    Topic: Non-oncology perspective
  • Alain Huriez, Venture Partner, Advent Venture Partners and Chairman, EPEMED
    Topic: Small diagnostic/technology perspective
  • Magali Gibou, Senior Regulatory Affairs Manager, Transgene S.A.
    Topic: Regulatory & small biotech perspective
  • Seong Chen, Project Leader, Strategic Initiatives, Global Business Development,
    F. Hoffmann-La Roche Ltd.
    Topic: Dx reimbursement perspective

Presenting Opportunities

Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business.

Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.

The forum is recognised as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners.

Sponsorship

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact
Sian Rodgers + 44 (0)203 463 4890 or by email: Sian Rodgers.

 
  Conference Guide
Conference Guide
Click cover above to view the Conference Guide
 
FORUM UPDATES
AGENDA
NOW ONLINE >>
ONLINE MEETING SYSTEM
NOW ONLINE >>
2013 Attendees now online.
View >>>
PRESENTING COMPANIES
2012 Presenting Companies
View >>>
Sachs on TwitterFollow us on Twitter @SachsAssociates
To learn more about presenting, exhibition
or sponsorship opportunities, please contact Sian Rodgers
+ 44 (0)203 463 4890 or by email: Sian Rodgers.
  Pharma Licensing
  Groups represented
  at the Forum include:
Abbott Pharmaceuticals Actelion Pharmaceuticals Bristol Meyers Squibb Esteve GlaxoSmithKline Helsinn Holding SA Ipsen Group Norgine Novartis Oncology F.Hoffmann-La Roche Ltd Sanofi R&D TEVA
 
  Financial
  Advisory/Investors
  attending include:
Abbott Biotech Ventures
Abingworth Management Ltd
Advent Venture Partners
Aravis S.A.
BB Biotech Ventures
Bergmann zur Hausen & Cie. GmbH
BioMedPartners AG
Breslin AG
Cancer Research Technology
Capricorn Venture Partners n.v.
Catalyst Capital Partners
Citi Group
Creathor Ventures
Cukierman Life Sciences
Forbion Capital Partners
Gilde Healthcare Partners
Global Life Science Ventures GmbH
High-Tech Gründerfonds Management
JSB Partners LP
Kurma Life Sciences Partners
LSP
Lundbeckfond Ventures
MedVenture Partners GmbH
Merck Serono Ventures
MPM Capital
Nextech Invest Ltd
Nomura Code Securities
Novartis Venture Fund
Omega Fund Management
OrbiMed Healthcare Fund Management
Osprey Capital Partners Inc.
Peppermint Venture Partners GmbH
Percipient Capital
Piper Jaffrey Ltd
Polar Capital
PwC
Roche Venture Fund
Rockport Venture Partners (BF)
Sectoral Asset Management
Sofinnova Partners
Sunstone Life Sciences Partners
SR One
Takeda Research Investment, Inc.
TL Asset & Interim Management
Ventac Partners
VIP Partners
Visium Asset Management
Wellington Partners
Ysios Capital Partners
Zürcher Kantonalbank
 
  Meeting Scheduler
1-2-1 Meeting system
 

 

 
  Zurich Sponsors and supporters